```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS  3  OCT 07  EPFULL enhanced with full implementation of EPC2000
 NEWS  4  OCT 07  Multiple databases enhanced for more flexible patent
                  number searching
 NEWS  5  OCT 22  Current-awareness alert (SDI) setup and editing
                  enhanced
 NEWS  6  OCT 22  WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                  Applications
 NEWS  7  OCT 24  CHEMLIST enhanced with intermediate list of
                  pre-registered REACH substances
 NEWS  8  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  9  NOV 26  MARPAT enhanced with FSORT command
 NEWS 10  NOV 26  MEDLINE year-end processing temporarily halts
                  availability of new fully-indexed citations
 NEWS 11  NOV 26  CHEMSAFE now available on STN Easy
 NEWS 12  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS 13  DEC 01  ChemPort single article sales feature unavailable
 NEWS 14  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS 15  DEC 17  Fifty-one pharmaceutical ingredients added to PS

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 11:28:28 ON 24 DEC 2008

=> b reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.21        0.21

FILE 'REGISTRY' ENTERED AT 11:28:39 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 DEC 2008  HIGHEST RN 1088779-12-7
DICTIONARY FILE UPDATES:  22 DEC 2008  HIGHEST RN 1088779-12-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e celecoxib/cn
E1            1     CELEC K/CN
E2            1     CELECOX/CN
E3            1 --> CELECOXIB/CN
E4            1     CELECOXIB CALCIUM/CN
E5            1     CELECOXIB LITHIUM/CN
E6            1     CELECOXIB POTASSIUM/CN
E7            1     CELECOXIB SODIUM/CN
E8            1     CELECOXIB SODIUM HYDRATE/CN
E9            1     CELECT AMINE/CN
E10           1     CELECT H 150/CN
E11           1     CELECT H 75/CN
E12           1     CELECT P 175/CN

=> s e3
L1            1 CELECOXIB/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   169590-42-5  REGISTRY
ED   Entered STN:  02 Nov 1995
CN   Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
     yl]-  (CA INDEX NAME)
OTHER NAMES:
CN   4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
     yl]benzenesulfonamide
```

CN Celebra
CN Celebrex
CN Celecox
CN *Celecoxib*
CN Celocoxib
CN SC 58635
CN YM 177
DR 184007-95-2, 194044-54-7
MF C17 H14 F3 N3 O2 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3237 REFERENCES IN FILE CA (1907 TO DATE)
77 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3256 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e propylene glycol/cn
E1 1 PROPYLENE FUMARATE POLYMER/CN
E2 1 PROPYLENE FUMARATE-PROPYLENE ISOPHTHALATE COPOLYMER/CN
E3 1 --> PROPYLENE GLYCOL/CN
E4 1 PROPYLENE GLYCOL (2-CHLORO-4-AMINOPHENYL) ETHER SULFURIC ACID ESTER/CN
E5 1 PROPYLENE GLYCOL B-MONOETHYL ETHER/CN
E6 1 PROPYLENE GLYCOL 1,2,3-PROPANETRIYL ETHER-TOLUENE DIISOCYANATE POLYMER/CN
E7 1 PROPYLENE GLYCOL 1,2-DIPROPIONATE/CN
E8 1 PROPYLENE GLYCOL 1,3-DITOSYLATE/CN
E9 1 PROPYLENE GLYCOL 1-(TERT-BUTYL ETHER)/CN
E10 1 PROPYLENE GLYCOL 1-BEHENATE/CN
E11 1 PROPYLENE GLYCOL 1-METHYL ETHER/CN

```
E12          1     PROPYLENE GLYCOL 1-METHYL ETHER 2-ACETATE/CN

=> s e3
L2           1 "PROPYLENE GLYCOL"/CN

=> d 12

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   57-55-6  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   1,2-Propanediol  (CA INDEX NAME)
OTHER NAMES:
CN   (±)-1,2-Propanediol
CN   (±)-Propylene glycol
CN   (RS)-1,2-Propanediol
CN   α-Propylene glycol
CN   1,2-(RS)-Propanediol
CN   1,2-Dihydroxypropane
CN   1,2-Propylene glycol
CN   1000PG
CN   2,3-Propanediol
CN   2-Hydroxypropanol
CN   Adeka PG
CN   Adeka Propylene Glycol PG-P
CN   DC 403
CN   DL-1,2-Propanediol
CN   dl-Propylene glycol
CN   Dowfrost
CN   Isopropylene glycol
CN   Methylethyl glycol
CN   Methylethylene glycol
CN   Monopropylene glycol
CN   NSC 69860
CN   Nybrine NFP
CN   PG 12
CN   PG-T
CN   PG-T (glycol)
CN   ProGlyc 55
CN   Propylene glycol
CN   Safewing MP-I 1938
CN   Safewing MP-IV 2001
CN   Sirlene
CN   Solar Winter Ban
CN   Solargard P
CN   Ucar 35
DR   63625-56-9, 4254-16-4, 190913-75-8
MF   C3 H8 O2
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX,
       CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE,
       ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB,
       IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PATDPASPC,
       PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA,
       ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

32647 REFERENCES IN FILE CA (1907 TO DATE)
3717 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
32747 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 15.22 TOTAL SESSION 15.43
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:29:33 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 23 Dec 2008 (20081223/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l1 and l2
3256 L1
32747 L2
L3 64 L1 AND L2

=> s l3 and (solvate or crystalline)
11283 SOLVATE
7474 SOLVATES
17238 SOLVATE
(SOLVATE OR SOLVATES)
89739 CRYSTALLINE
303 CRYSTALLINES
90014 CRYSTALLINE

```
              (CRYSTALLINE OR CRYSTALLINES)
        380842 CRYST
          1802 CRYSTS
        382111 CRYST
              (CRYST OR CRYSTS)
        414930 CRYSTALLINE
              (CRYSTALLINE OR CRYST)
L4            4 L3 AND (SOLVATE OR CRYSTALLINE)

=> d l4 1-4 ibib abs

L4   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:63611  CAPLUS
DOCUMENT NUMBER:          146:148846
TITLE:                    Pharmaceutical propylene glycol solvate
                          compositions and method for preparation thereof
INVENTOR(S):              Tawa, Mark; Almarsson, Orn; Remenar, Julius
PATENT ASSIGNEE(S):       Transform Pharmaceuticals, Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of Appl.
                          No. PCT/US03/41273.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   18
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     US 20070015841       A1    20070118    US 2003-747742         20031229
     US 6559293           B1    20030506    US 2002-232589         20020903
     US 20030166581       A1    20030904    US 2002-295995         20021118
     US 6699840           B2    20040302
     US 20030224006       A1    20031204    US 2003-378956         20030303
     US 20040019211       A1    20040129    US 2003-449307         20030530
     US 7078526           B2    20060718
     WO 2004000284        A1    20031231    WO 2003-US19574        20030620
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20050025791       A1    20050203    US 2003-601092         20030620
     US 20040053853       A1    20040318    US 2003-637829         20030808
     WO 2004078161        A1    20040916    WO 2003-US27772        20030904
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
```

US 20070026078	A1	20070201	US 2003-660202	20030911	
WO 2004061433	A1	20040722	WO 2003-US41273	20031224	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,				
	NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,				
	TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004063152	A2	20040729	WO 2004-US400	20040108	
WO 2004063152	A3	20041111			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
WO 2004089313	A2	20041021	WO 2004-US9947	20040331	
WO 2004089313	A3	20051124			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				
ZA 2004007377	A	20051004	ZA 2004-7377	20040914	
US 20060140985	A1	20060629	US 2005-541703	20050708	
PRIORITY APPLN. INFO.:			US 2002-356764P	P	20020215
			US 2002-360768P	P	20020301
			US 2002-380288P	P	20020515
			US 2002-384152P	P	20020531
			US 2002-390881P	P	20020621
			US 2002-406974P	P	20020830
			US 2002-232589	A1	20020903
			US 2002-426275P	P	20021114
			US 2002-427086P	P	20021115
			US 2002-295995	A3	20021118
			US 2002-428515P	P	20021122
			US 2002-429515P	P	20021126
			US 2002-437516P	P	20021230
			US 2003-439282P	P	20030110
			US 2003-441335P	P	20030121
			US 2003-444315P	P	20030131
			US 2003-451213P	P	20030228
			US 2003-378956	A2	20030303
			US 2003-456027P	P	20030318
			US 2003-456608P	P	20030321
			US 2003-459501P	P	20030401
			US 2003-463962P	P	20030418
			US 2003-449307	A2	20030530
			US 2003-601092	A2	20030620
			WO 2003-US19574	A2	20030620
			US 2003-486713P	P	20030711

US 2003-487064P	P	20030711
US 2003-637829	A2	20030808
WO 2003-US27772	A2	20030904
US 2003-660202	A2	20030911
WO 2003-US41273	A2	20031224
US 2003-439283P	P	20030110
WO 2003-US28982	A2	20030916
US 2003-747742	A	20031229
WO 2003-US41642	A	20031229
WO 2004-US400	W	20040108
WO 2004-US6288	A	20040226
US 2004-548343P	P	20040227

AB The present invention provides a pharmaceutical composition comprising a propylene glycol *solvate* of a drug which is hygroscopic or has low aqueous solubility It has surprisingly been found that by using propylene glycol to form a *solvate* of a hygroscopic drug, the hygroscopicity of the drug is decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2006:1251802 CAPLUS
DOCUMENT NUMBER:	146:33009
TITLE:	Injections containing COX II inhibitors and NSAID for analgesic and antiinflammatory action
INVENTOR(S):	Jain, Rajesh; Jindal, Kour Chand; Singh, Sukhjeet; Boldhane, Sanjay
PATENT ASSIGNEE(S):	Panacea Biotec Ltd., India
SOURCE:	PCT Int. Appl., 33pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006126214	A2	20061130	WO 2006-IN177	20060525
WO 2006126214	A3	20070607		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005DE01357	A	20061208	IN 2005-DE1357	20050527
AU 2006250765	A1	20061130	AU 2006-250765	20060525
CA 2609242	A1	20061130	CA 2006-2609242	20060525
EP 1895983	A2	20080312	EP 2006-756263	20060525
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

JP 2008542260	T	20081127	JP 2008-513009		20060525
MX 200714862	A	20080221	MX 2007-14862		20071126
NO 2007006468	A	20080227	NO 2007-6468		20071214
KR 2008016689	A	20080221	KR 2007-730585		20071227
CN 101217939	A	20080709	CN 2006-80025093		20080109
PRIORITY APPLN. INFO.:			IN 2005-DE1357	A	20050527
			WO 2006-IN177	W	20060525

AB Novel and highly stable injectable pharmaceutical compns. comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogs, isomers, polymorphs, *solvates*, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by i.m. or i.v. route; process of preparing such compns. and therapeutic methods of using such compns. are provided. The analgesic and anti-inflammatory injectable compns. of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurol. pain and pain associated with sciatica and spondylitis, and the like, and/or chronic painful conditions, and/or a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis, and/or other associated disorders such as inflammation, fever, allergy, or the like. For example, injections contained nimesulide, PEG, propylene glycol, glycine and sodium hydroxide.

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:589401 CAPLUS
DOCUMENT NUMBER:	141:128859
TITLE:	Pharmaceutical propylene glycol *solvate* compositions
INVENTOR(S):	Tawa, Mark; Almarsson, Oern; Remenar, Julius
PATENT ASSIGNEE(S):	Transform Pharmaceuticals, Inc., USA
SOURCE:	PCT Int. Appl., 317 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	18
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6559293	B1	20030506	US 2002-232589	20020903
WO 2004000284	A1	20031231	WO 2003-US19574	20030620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,			

PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050025791 A1 20050203 US 2003-601092 20030620

WO 2004026235 A2 20040401 WO 2003-US28982 20030916

WO 2004026235 A3 20040805

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2004061433 A1 20040722 WO 2003-US41273 20031224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003300452 A1 20040729 AU 2003-300452 20031229

WO 2004089313 A2 20041021 WO 2004-US9947 20040331

WO 2004089313 A3 20051124

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 20060140985 A1 20060629 US 2005-541703 20050708

US 20060223794 A1 20061005 US 2005-551014 20050929

PRIORITY APPLN. INFO.: US 2002-232589 A 20020903

US 2002-437516P P 20021230

US 2003-441335P P 20030121

US 2003-456027P P 20030318

US 2003-456608P P 20030321

US 2003-459501P P 20030401

US 2003-601092 A 20030620

WO 2003-US19574 A 20030620

US 2003-486713P P 20030711

WO 2003-US28982 A 20030916

WO 2003-US41273 A 20031224

US 2002-356764P P 20020215

US 2002-360768P P 20020301

US 2002-380288P	P	20020515
US 2002-384152P	P	20020531
US 2002-390881P	P	20020621
US 2002-406974P	P	20020830
US 2002-412459P	P	20020920
US 2002-426275P	P	20021114
US 2002-427086P	P	20021115
US 2002-295995	A3	20021118
US 2002-428515P	P	20021122
US 2002-429515P	P	20021126
US 2003-439282P	P	20030110
US 2003-439283P	P	20030110
US 2003-444315P	P	20030131
US 2003-451213P	P	20030228
US 2003-378956	A	20030303
US 2003-463962P	P	20030418
US 2003-449307	A	20030530
US 2003-487064P	P	20030711
US 2003-637829	A	20030808
WO 2003-US27772	A2	20030904
US 2003-660202	A2	20030911
US 2003-747742	A	20031229
US 2004-747742	A1	20031229
WO 2003-US41642	W	20031229
WO 2004-US400	W	20040108
WO 2004-US6288	A	20040226
US 2004-548343P	P	20040227
WO 2004-US9947	W	20040331

AB The invention relates to pharmaceutical compns. comprising propylene glycol *solvates* of active pharmaceutical ingredients (APIs) which are hygroscopic or has low aqueous solubility The composition comprises *solvate* characterized by (i) the mole ratio of propylene glycol to API in the range of 0.25 to 2; (ii) a *crystalline* form, (iii) a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property, (iv) stability to temps. of up to 50° under a stream of gas in a thermogravimetric anal. apparatus, (v) the API is optionally in the form of a metal salt, such as an alkali or an alkaline earth metal salt, (vi) the API has low aqueous solubility and is selected from steroid drugs, and (vii) the composition further comprises a pharmaceutically-acceptable diluent, excipient or carrier. A method for preparing a propylene glycol *solvate* of an API comprises (a) contacting propylene glycol with an API in solution, (b) crystallizing a propylene glycol *solvate* of the API from the solution, and (c) isolating the *solvate*. For example, to a solution of celecoxib (253 mg, 0.664 mmol) in di-Et ether (6 mL) was added propylene glycol (0.075 mL, 102 mmol). To the clear solution was added potassium t-butoxide in THF (1 M, 0.66 mL, 0.66 mmol). Crystals immediately began to form and after 5 min the solid had completely crystallized The *crystalline* salt form was found to be a 1:1 propylene glycol *solvate* of celecoxib potassium salt.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:269999 CAPLUS
DOCUMENT NUMBER:	140:309372
TITLE:	Pharmaceutical compositions with improved dissolution
INVENTOR(S):	Remenar, Julius; Peterson, Matthew; Almarsson, Om; Guzman, Hector; Chen, Hongming; Tawa, Mark; Oliveira, Mark

PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026235	A2	20040401	WO 2003-US28982	20030916
WO 2004026235	A3	20040805		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003267231	A1	20040408	AU 2003-267231	20030916
CA 2511881	A1	20040722	CA 2003-2511881	20031224
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003303591	A1	20040729	AU 2003-303591	20031224
EP 1579198	A1	20050928	EP 2003-808567	20031224
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006517527	T	20060727	JP 2005-508617	20031224
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003300452	A1	20040729	AU 2003-300452	20031229
US 20060052432	A1	20060309	US 2005-528244	20050317
US 20060134198	A1	20060622	US 2005-541216	20050629
US 20060140985	A1	20060629	US 2005-541703	20050708
PRIORITY APPLN. INFO.:			US 2002-412459P P	20020920
			US 2002-426275P P	20021114
			US 2002-427086P P	20021115

US 2002-429515P	P	20021126
US 2002-437516P	P	20021230
US 2003-456027P	P	20030318
US 2002-232589	A	20020903
US 2003-439283P	P	20030110
US 2003-441335P	P	20030121
US 2003-451213P	P	20030228
US 2003-378956	A	20030303
US 2003-456608P	P	20030321
US 2003-459501P	P	20030401
US 2003-449307	A	20030530
US 2003-601092	A	20030620
WO 2003-US19574	A	20030620
US 2003-486713P	P	20030711
US 2003-487064P	P	20030711
US 2003-637829	A	20030808
WO 2003-US27772	A	20030904
US 2003-660202	A	20030911
WO 2003-US28982	W	20030916
WO 2003-US41273	W	20031224
WO 2003-US41642	W	20031229
WO 2004-US400	W	20040108

AB The invention relates to methods of screening mixts. containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissoln. and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer. For example, celecoxib sodium salt was prepared from 126.3 mg of celecoxib in isopropanol and sodium ethoxide (21% ethanol solution). Water was added to a 1:4 mixture of celecoxib sodium salt and polyvinylpyrrolidone to obtain a clear solution The solution was stable for at least 15 min, after which time, crystals of neutral celecoxib began to form. *Crystalline* neutral celecoxib did not dissolve when added to aqueous polyvinylpyrrolidone or when water was added to a dry blend of neutral *crystalline* celecoxib and polyvinylpyrrolidone.

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.36	31.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:30:05 ON 24 DEC 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

```
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * * *   Welcome to STN International   * * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 15   CAOLD to be discontinued on December 31, 2008
 NEWS  3  OCT 07   EPFULL enhanced with full implementation of EPC2000
 NEWS  4  OCT 07   Multiple databases enhanced for more flexible patent
                   number searching
 NEWS  5  OCT 22   Current-awareness alert (SDI) setup and editing
                   enhanced
 NEWS  6  OCT 22   WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                   Applications
 NEWS  7  OCT 24   CHEMLIST enhanced with intermediate list of
                   pre-registered REACH substances
 NEWS  8  NOV 21   CAS patent coverage to include exemplified prophetic
                   substances identified in English-, French-, German-,
                   and Japanese-language basic patents from 2004-present
 NEWS  9  NOV 26   MARPAT enhanced with FSORT command
 NEWS 10  NOV 26   MEDLINE year-end processing temporarily halts
                   availability of new fully-indexed citations
 NEWS 11  NOV 26   CHEMSAFE now available on STN Easy
 NEWS 12  NOV 26   Two new SET commands increase convenience of STN
                   searching
 NEWS 13  DEC 01   ChemPort single article sales feature unavailable
 NEWS 14  DEC 12   GBFULL now offers single source for full-text
                   coverage of complete UK patent families
 NEWS 15  DEC 17   Fifty-one pharmaceutical ingredients added to PS

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:56:21 ON 24 DEC 2008

=> b reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:56:55 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 DEC 2008 HIGHEST RN 1089286-03-2
DICTIONARY FILE UPDATES: 23 DEC 2008 HIGHEST RN 1089286-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> e 57-55-6/rn
E1            1     57-53-4/RN
E2            1     57-54-5/RN
E3            1 --> 57-55-6/RN
E4            1     57-56-7/RN
E5            1     57-57-8/RN
E6            1     57-60-3/RN
E7            1     57-61-4/RN
E8            1     57-62-5/RN
E9            1     57-63-6/RN
E10           1     57-64-7/RN
E11           1     57-65-8/RN
E12           1     57-66-9/RN

=> s e3
L1            1 57-55-6/RN

=> b caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.46       0.67

FILE 'CAPLUS' ENTERED AT 13:57:13 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE COVERS 1907 - 24 Dec 2008  VOL 149 ISS 26
FILE LAST UPDATED: 23 Dec 2008  (20081223/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l1 and solvate
         32747 L1
         11283 SOLVATE
          7474 SOLVATES
         17238 SOLVATE
                (SOLVATE OR SOLVATES)
L2          85 L1 AND SOLVATE

=> s l2 and py<=2002
      22964578 PY<=2002
L3          34 L2 AND PY<=2002

=> s l3 and (NSAID or celecoxib or celebrex or sulfonamide or COX?)
          6662 NSAID
          6397 NSAIDS
          9621 NSAID
                (NSAID OR NSAIDS)
          3596 CELECOXIB
           291 CELEBREX
         23682 SULFONAMIDE
         19058 SULFONAMIDES
         33661 SULFONAMIDE
                (SULFONAMIDE OR SULFONAMIDES)
         40519 COX?
L4           2 L3 AND (NSAID OR CELECOXIB OR CELEBREX OR SULFONAMIDE OR COX?)

=> d l4 ibib abs 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2002:964313  CAPLUS
DOCUMENT NUMBER:          138:55745
TITLE:                    Preparation of substituted 3-phenyl-2-alkoxypropanoic
                          acids and analogs as modulators of peroxisome
                          proliferator activated receptors for treatment of
                          diabetes and related conditions
INVENTOR(S):              Brooks, Dawn Alisa; Warshawsky, Alan M.;
                          Montrose-Rafezadeh, Chahrzad; Reifel-Miller, Anne;
                          Prieto, Lourdes; Rojo, Isabel; Martin, Jose Alfredo;
                          Gonzales Garcia, Maria Rosario; Torrado, Alicia;
                          Ferritto Crespo, Rafael; Lamas-Peteira, Carlos;
                          Martin-Ortega Finger, Maria; Ardecky, Robert J.
PATENT ASSIGNEE(S):       Eli Lilly and Company, USA; Ligand Pharmaceuticals
                          Incorporated
SOURCE:                   PCT Int. Appl., 458 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
```

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100813	A2	20021219	WO 2002-US16950	20020530 <--
WO 2002100813	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449256	A1	20021219	CA 2002-2449256	20020530 <--
AU 2002312147	A1	20021223	AU 2002-312147	20020530 <--
EE 200400001	A	20040216	EE 2004-1	20020530
EP 1392637	A2	20040303	EP 2002-739503	20020530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010190	A	20040406	BR 2002-10190	20020530
CN 1543451	A	20041103	CN 2002-811530	20020530
HU 2004000280	A2	20050128	HU 2004-280	20020530
HU 2004000280	A3	20060130		
JP 2005509590	T	20050414	JP 2003-503584	20020530
NZ 529351	A	20060127	NZ 2002-529351	20020530
IN 2003KN01456	A	20060414	IN 2003-KN1456	20031110
ZA 2003008863	A	20050214	ZA 2003-8863	20031113
US 20050020684	A1	20050127	US 2003-479262	20031201
US 7192982	B2	20070320		
MX 2003PA11201	A	20040226	MX 2003-PA11201	20031204
US 20070276138	A1	20071129	US 2006-637223	20061211

PRIORITY APPLN. INFO.:			
US 2001-297144P	P	20010607	
WO 2002-US16950	W	20020530	
US 2003-479262	A1	20031201	

OTHER SOURCE(S): MARPAT 138:55745
GI



I



II

AB Title compds. I [wherein Ar = (un)substituted aryl; Q = covalent bond, CH2, CH2CH2, CH2CH2CH2, or CH2CH2CH2CH2; W = (un)substituted (hetero)alkylene from 2–10 atoms in length in which 1 or more methylene groups have been replaced with CH=CH, C.tplbond.C, O, CO, NR7, NR7CO, C(=NOH), S, SO, SO2, or CHNR7R8; ring A is optionally substituted with up to 4 substituents in addition to R1; R1 = (CH2)nCH(OR2)(CH2)mE, CH=C(OR2)(CH2)mE, (CH2)nCHY(CH2)mE, or CH=CY(CH2)mE; E = CO2R3, alkylnitrile, carboxamide, or (un)substituted *sulfonamide*, acylsulfonamide, or tetrazole; R2 = H, haloalkyl, COR4, CO2R4, CONR5R6, CSR4, CSOR4, CSNR5R6, or (un)substituted aliphatic group, aralkyl, or aryl; Y = O, CH2, CH2CH2, or CH=CH bonded ortho to R1 on ring A; R3–R8 = independently H or (un)substituted aliphatic group or aryl; m and n = independently 0–2; or pharmaceutically acceptable salts, hydrates, stereoisomers, or *solvates* thereof] were prepared by solution phase and solid phase synthetic methods as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, (S)-2-methoxy-3-hydroxyphenylpropanoic acid Et ester was treated with Ph triflimide to give the 4-trifluoromethanesulfonyloxyphenyl derivative (97%). Substitution with propargyl alc. in the presence of PdCl2(PPh3)2 and TEA in DMF afforded the 4-(3-hydroxyprop-1-ynyl)phenyl intermediate (32%), which was coupled with 4-phenylphenol using the Mitsunobu procedure to give II. Binding and cotransfection studies showed that many of the compds. of the invention are selective PPARγ agonists or PPARα/PPARγ co-agonists (no data). Thus, I are useful for the treatment of hyperglycemia, dyslipidemia, Type I or II diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, polycystic ovarian syndrome, anorexia nervosa, cardiovascular disease or other diseases where insulin resistance is a component (no data).

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1991:49473 CAPLUS
DOCUMENT NUMBER:	114:49473
ORIGINAL REFERENCE NO.:	114:8441a,8444a
TITLE:	Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs
AUTHOR(S):	Rubino, Joseph T.; Thomas, Elizabeth
CORPORATE SOURCE:	Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599-7360, USA
SOURCE:	International Journal of Pharmaceutics (*1990*), 65(1-2), 141-5 CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The solubilities of the Na salts of some *sulfonamides*, barbiturates and hydantoins were determined in mixts. of propylene glycol and water. In many cases, the solubilities of the salts in the mixed solvents were lower than those in water, however, several compds. exhibited enhanced solubilities in the mixed solvents. This unexpected increase in solubility was not related to the lipophilicity of the acidic forms of the drugs and occurred in at least one member of each group of compds. Anal. of the solid phase which had been equilibrated with each solvent indicated the formation of crystal hydrates for most of the solutes, and in at least one instance, mixed *solvates*. These compds. could be categorized on the basis of their desolvation temps. Those compds. with

low temps. of desolvation had increased solubilities in propylene glycol-water mixts. while compds. with high desolvation temps. had decreased solubilities in the mixed solvents. These data indicate that crystal hydrate formation plays a significant role in determining if a cosolvent can be used to enhance the solubilities of certain sodium salts.

=> d l3 1- ti
YOU HAVE REQUESTED DATA FROM 34 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of substituted 3-phenyl-2-alkoxypropanoic acids and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions

L3 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical aerosol formulation

L3 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of eplerenone crystalline form

L3 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceuticals containing alkoxybenzimidazoles for inhibition of gastric acid secretion

L3 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Compositions containing 4-(4-chloro-2-hydroxybenzoyl)aminobutyric acid and its salts for delivering active agents

L3 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical anti-inflammatory aerosol formulation containing a hydrofluoroalkane propellant

L3 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Dry blend of methoxybenzimidazole derivs. for oral dosage forms

L3 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Cyclodextrin-containing pharmaceutical formulations for benzimidazole derivatives

L3 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Oily compositions containing highly fat-soluble drugs

L3 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Eplerenone crystalline form exhibiting enhanced dissolution rate

L3 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Eplerenone crystalline form

L3 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceuticals containing alkoxybenzimidazoles for inhibition of gastric acid secretion

L3 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical compositions comprising a 1,2,4-triazolo[1,5-a]pyrimidine derivative and cyclodextrin

L3 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN

TI Medicinal composition for percutaneous administration

L3 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical compositions containing cyclodextrins and taxoids

L3 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing

L3 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Dicyclanil polymorphs and hydrates and their preparation

L3 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation and formulation of an androstenone derivative for treatment of androgen-related diseases

L3 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Role of cosolvent in hydrophobic interactions. Calorimetric studies in alkanols in concentrated aqueous solutions of urea at 298 K

L3 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Minimizing precipitation in parenteral pharmaceutical compositions containing GF120918A

L3 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Time-resolved fluorescence relaxation of 3-methyllumiflavin in polar solution

L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Formation and properties of pentacoordinate silicon glycolates

L3 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical compositions comprising 5-HT1 receptor agonists and absorption enhancers

L3 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs

L3 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Thrombolytic pharmaceutical combinations containing a piperidinylcyclopentylheptenoic acid derivative

L3 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Spectroscopic study of the solvolysis products of silicon tetrafluoride by 1,2-diols

L3 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique

L3 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Effect of crystallinity and excipients on absorption and excretion patterns of ibuprofen and lorazepam

L3 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2008 ACS on STN
TI Outer-sphere interaction of *solvates* of aluminum and gallium with competing anions in a solution of 1,2-propanediol

```
L3   ANSWER 30 OF 34  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Cefatrizine propylene glycol solvate

L3   ANSWER 31 OF 34  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Cholesterol solubility in organic solvents

L3   ANSWER 32 OF 34  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   The velocity of cleavage with lead tetraacetate in relation to the
     constitution and configuration of the glycol. III

L3   ANSWER 33 OF 34  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Solubility of iodine in glycol-water solutions

L3   ANSWER 34 OF 34  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Lead chloride-ethylene glycol-water system at 25°


=> d his

     (FILE 'HOME' ENTERED AT 13:56:21 ON 24 DEC 2008)

     FILE 'REGISTRY' ENTERED AT 13:56:55 ON 24 DEC 2008
               E 57-55-6/RN
L1            1 S E3

     FILE 'CAPLUS' ENTERED AT 13:57:13 ON 24 DEC 2008
L2           85 S L1 AND SOLVATE
L3           34 S L2 AND PY<=2002
L4            2 S L3 AND (NSAID OR CELECOXIB OR CELEBREX OR SULFONAMIDE OR COX?

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     35.78      36.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -1.60      -1.60

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:00:33 ON 24 DEC 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 14:07:33 ON 24 DEC 2008
FILE 'CAPLUS' ENTERED AT 14:07:33 ON 24 DEC 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    35.78      36.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -1.60      -1.60

=> b reg
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  35.78      36.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -1.60      -1.60

FILE 'REGISTRY' ENTERED AT 14:07:40 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 DEC 2008  HIGHEST RN 1089286-03-2
DICTIONARY FILE UPDATES:  23 DEC 2008  HIGHEST RN 1089286-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e celecoxib
E1            3     CELEC/BI
E2            1     CELECOX/BI
E3            7 --> CELECOXIB/BI
E4            6     CELECT/BI
E5            1     CELECTOL/BI
E6            1     CELEHEX/BI
E7            1     CELEKA/BI
E8            1     CELELL/BI
E9            1     CELELLOSE/BI
E10           9     CELEMIA/BI
E11           1     CELEMIC/BI
E12          11     CELEN/BI

=> e celecoxib/cn
E1            1     CELEC K/CN
E2            1     CELECOX/CN
E3            1 --> CELECOXIB/CN
E4            1     CELECOXIB CALCIUM/CN
```

```
E5              1     CELECOXIB LITHIUM/CN
E6              1     CELECOXIB POTASSIUM/CN
E7              1     CELECOXIB SODIUM/CN
E8              1     CELECOXIB SODIUM HYDRATE/CN
E9              1     CELECT AMINE/CN
E10             1     CELECT H 150/CN
E11             1     CELECT H 75/CN
E12             1     CELECT P 175/CN

=> e 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide/cn
E1              1     4,N-DIMETHYLQUINOLINIUM IODIDE/CN
E2              1     4,STILBENAMINE, N,N-DIMETHYL-2',4'-BIS(PHENYLSULFONYL)-/CN
E3              0 --> 4-5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL BENZEN
                      ESULFONAMIDE/CN
E4              1     4-(((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)METHYL)BENZOIC A
                      CID/CN
E5              1     4-(((((1-CARBOXY-2-MERCAPTOETHYL)CARBAMOYL)METHOXY)CARBONYL)
                      AMINO)-2-HYDROXYBENZOIC ACID/CN
E6              1     4-(((((1R,2S)-2-(((3AR,4R,9BR)-4-PHENYL-2,3,3A,4,5,9B-HEXAHY
                      DRO-1H-PYRROLO(3,2-C)QUINOLIN-1-YL)CARBONYL)CYCLOHEXYL)AMINO
                      )CARBONYL)AMINO)BENZAMIDE/CN
E7              1     4-(((((5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO)CARBONYL)AMINO)ME
                      THYL)BENZENESULFONAMIDE/CN
E8              1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-1
                      -NAPHTHYL N,N-DIETHYLCARBAMATE/CN
E9              1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2
                      ,3,5-TRIMETHYLBENZOIC ACID/CN
E10             1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2
                      ,3,5-TRIMETHYLPHENYL ACETATE/CN
E11             1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2
                      -NAPHTHOIC ACID/CN
E12             1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2
                      -NAPHTHYL ACETATE/CN

=> e
E13             1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2
                      -NAPHTHYL N,N-DIMETHYLCARBAMATE/CN
E14             1     4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO
                      -9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-3
                      ,5-DIMETHYLPHENYL ACETATE/CN
E15             1     4-(((((FLUOREN-9-YLMETHOXYCARBONYLAMINO))THIOXOMETHYL)AMINO)
                      METHYL)-4-FLUOROPIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTE
                      R/CN
E16             1     4-(((((P-NITROBENZYL)OXY)CARBONYL)AMINO)METHYL)ANILINE/CN
E17             1     4-((((1,1'-BIPHENYL)-4-YL)CARBONYL)AMINO)-2-(METHYLTHIO)-1-P
                      HENYL-1H-IMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER/CN
E18             1     4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)BENZENAMINE
                      /CN
E19             1     4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)PHENOL/CN
E20             1     4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)PYRIDINE/CN
E21             1     4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-2-PHENYLBUTANOIC
                       ACID/CN
E22             1     4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-3-PHENYLBUTANOIC
```

```
                    ACID/CN
E23          1      4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-4-(3-METHYLPHENY
                    L)BUTANOIC ACID/CN
E24          1      4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-4-PHENYLBUTANOIC
                    ACID/CN

=> e
E25          1      4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)CYCLOHEXANECARBOX
                    YLIC ACID/CN
E26          1      4-((((1,3-BENZOTHIAZOL-2-YL)((4-NITROPHENYL)SULFONYL)AMINO)C
                    ARBOTHIOYL)((4-NITROPHENYL)SULFONYL)AMINO)PHTHALIC ACID/CN
E27          1      4-((((1-((2,4-DICHLORO-3-(((2-METHYL-4-(1H-1,2,4-TRIAZOL-1-Y
                    L)-8-QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINY
                    L)CARBONYL)AMINO)METHYL)-1-PIPERIDINEACETIC ACID 1,1-DIMETHY
                    LETHYL ESTER/CN
E28          1      4-((((1-((2,4-DICHLORO-3-(((2-METHYL-4-(1H-1,2,4-TRIAZOL-1-Y
                    L)-8-QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINY
                    L)CARBONYL)AMINO)METHYL)-1-PIPERIDINECARBOXYLIC ACID 1,1-DIM
                    ETHYLETHYL ESTER/CN
E29          1      4-((((1-((2,4-DICHLORO-3-(((2-METHYL-4-(1H-1,2,4-TRIAZOL-1-Y
                    L)-8-QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2-(S)-PYRROLIDIN
                    YL)CARBONYL)AMINO)METHYL)-1-PIPERIDINEACETIC ACID BISTRIFLUO
                    ROACETATE/CN
E30          1      4-((((1-((2,4-DICHLORO-3-(((2-METHYL-4-(1H-PYRAZOL-1-YL)-8-Q
                    UINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINYL)CARB
                    ONYL)AMINO)METHYL)-1-PIPERIDINECARBOXYLIC ACID 1,1-DIMETHYLE
                    THYL ESTER/CN
E31          1      4-((((1-((2,4-DICHLORO-3-(((4-(1H-IMIDAZOL-1-YL)-2-METHYL-8-
                    QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINYL)CAR
                    BONYL)AMINO)METHYL)-Γ-OXO-1-PIPERIDINEBUTANOIC ACID/CN
E32          1      4-((((1-((2,4-DICHLORO-3-(((4-(1H-IMIDAZOL-1-YL)-2-METHYL-8-
                    QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINYL)CAR
                    BONYL)AMINO)METHYL)-1-PIPERIDINEACETIC ACID 1,1-DIMETHYLETHY
                    L ESTER/CN
E33          1      4-((((1-((2,4-DICHLORO-3-(((4-(1H-IMIDAZOL-1-YL)-2-METHYL-8-
                    QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINYL)CAR
                    BONYL)AMINO)METHYL)-1-PIPERIDINEBUTANOIC ACID/CN
E34          1      4-((((1-((2,4-DICHLORO-3-(((4-(1H-IMIDAZOL-1-YL)-2-METHYL-8-
                    QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINYL)CAR
                    BONYL)AMINO)METHYL)-1-PIPERIDINECARBOXYLIC ACID 1,1-DIMETHYL
                    ETHYL ESTER/CN
E35          1      4-((((1-((2,4-DICHLORO-3-(((4-(1H-IMIDAZOL-1-YL)-2-METHYL-8-
                    QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2(S)-PYRROLIDINYL)CAR
                    BONYL)AMINO)METHYL)-1-PIPERIDINEPROPANOIC ACID/CN
E36          1      4-((((1-((2,4-DICHLORO-3-(((4-(1H-IMIDAZOL-1-YL)-2-METHYL-8-
                    QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)-2-(S)-PYRROLIDINYL)CA
                    RBONYL)AMINO)METHYL)-B-OXO-1-PIPERIDINEPROPANOIC ACID 1
                    ,1-DIMETHYLETHYL EST/CN

=> b stng
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY     SESSION
FULL ESTIMATED COST                                 0.46       36.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY     SESSION
CA SUBSCRIBER PRICE                                 0.00       -1.60

FILE 'STNGUIDE' ENTERED AT 14:08:32 ON 24 DEC 2008
```

```
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2008 (20081219/UP).

=>
=> d his

     (FILE 'HOME' ENTERED AT 13:56:21 ON 24 DEC 2008)

     FILE 'REGISTRY' ENTERED AT 13:56:55 ON 24 DEC 2008
               E 57-55-6/RN
L1           1 S E3

     FILE 'CAPLUS' ENTERED AT 13:57:13 ON 24 DEC 2008
L2          85 S L1 AND SOLVATE
L3          34 S L2 AND PY<=2002
L4           2 S L3 AND (NSAID OR CELECOXIB OR CELEBREX OR SULFONAMIDE OR COX?

     FILE 'REGISTRY' ENTERED AT 14:07:40 ON 24 DEC 2008
               E CELECOXIB
               E CELECOXIB/CN
               E 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENE

     FILE 'STNGUIDE' ENTERED AT 14:08:32 ON 24 DEC 2008

=> b caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 1.14      38.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00      -1.60

FILE 'CAPLUS' ENTERED AT 14:19:50 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 24 Dec 2008  VOL 149 ISS 26
FILE LAST UPDATED: 23 Dec 2008  (20081223/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
```

```
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s us20070015841/pn
L5             7 US20070015841/PN

=> analyze l5
ENTER ANSWER NUMBER OR RANGE (1-):1-
ENTER DISPLAY CODE (TI) OR ?:rn
L6           ANALYZE L5 1- RN :     144 TERMS

=> b reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                14.25      52.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00      -1.60

FILE 'REGISTRY' ENTERED AT 14:20:30 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 DEC 2008  HIGHEST RN 1089286-03-2
DICTIONARY FILE UPDATES:  23 DEC 2008  HIGHEST RN 1089286-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l6
L7           144 L6

=> s l7 and glycol/cns
         46328 GLYCOL/CNS
L8           4 L7 AND GLYCOL/CNS

=> d l8 1-4

L8   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   106392-12-5  REGISTRY
ED   Entered STN:  31 Jan 1987
CN   Oxirane, 2-methyl-, polymer with oxirane, block  (CA INDEX NAME)
```

OTHER NAMES:
CN Adeka 25R1
CN Adeka 25R2
CN Adeka CM 381
CN Adeka L 61
CN Adeka Pluronic 25R2
CN Adekanol L 44
CN Antarox 17R2
CN Antarox 25R2
CN Antarox B 25
CN Antarox F 108
CN Antarox F 68
CN Antarox F 88
CN Antarox F 88FL
CN Antarox L 61
CN Antarox L 64
CN Antarox L 72
CN Antarox P 104
CN Antarox P 84
CN Arco Polyol R 2633
CN Arcol E 351
CN B 053
CN BASF-L 101
CN Block polyethylene-polypropylene glycol
CN Block polyoxyethylene-polyoxypropylene
CN Breox BL 19-10
CN Caradol ED 56-07
CN Cirrasol ALN-WS
CN Conion AEP 1220
CN Crisvon Assistor SD 14
CN CRL 1029
CN CRL 1190
CN CRL 1605
CN CRL 8131
CN CRL 8142
CN D 500
CN D 500 (polyglycol)
CN DC 100
CN Dehypon KE 3557
CN Detalan
CN Dissolvan 4411
CN DO 97
CN Dowfax 30C05
CN ED 56
CN Emkarox VG 681W
CN Empilan P 7068
CN Emulgen PP 230
CN Emulsogen 3510
CN Emulsogen V 1816
CN EP 3028
CN Epan 450
CN Ethylene glycol-propylene glycol block copolymer
CN Ethylene oxide-propylene oxide block copolymer dipropylene glycol ether
CN Ethylene oxide-propylene oxide block copolymer ether with ethylene glycol
CN Ethylene oxide-propylene oxide block copolymer, ether with propylene glycol (2:1)
CN Polyethylene glycol-polypropylene glycol block copolymer

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

DR 912934-92-0, 874281-09-1, 11104-97-5, 162774-62-1, 163516-02-7, 124057-62-1, 121089-00-7, 134092-42-5, 96639-37-1, 96958-14-4, 99040-06-9, 106138-19-6, 113441-83-1, 115742-90-0, 108688-61-5, 108688-62-6, 37349-41-0, 70226-19-6, 72231-62-0, 77108-15-7, 80456-04-8, 144638-32-4, 83589-65-5, 86904-45-2, 106899-85-8, 107498-07-7, 108340-62-1, 178463-44-0, 188815-93-2, 194165-56-5, 197179-49-0, 200338-43-8, 200338-47-2, 211389-05-8, 238075-26-8, 351002-57-8, 355134-17-7, 406160-61-0, 441053-13-0, 441053-14-1

MF (C3 H6 O . C2 H4 O)x

CI PMS, COM

PCT Polyether, Polyether formed

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, IMSDRUGNEWS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)

CM 1

CRN 75-56-9

CMF C3 H6 O

CM 2

CRN 75-21-8

CMF C2 H4 O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12823 REFERENCES IN FILE CA (1907 TO DATE)
1042 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12877 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN

RN *9004-96-0* REGISTRY

ED Entered STN: 16 Nov 1984

CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecen-1-yl]-ω-hydroxy- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN *Oleic acid, monoester with polyethylene glycol (8CI)*

OTHER NAMES:

CN Adeka Estol OEG 204

CN Agnique PEG 400MO

CN Akyporox O 50
CN Alkamuls 400MO
CN Alkamuls A 2
CN Alkasurf O 14
CN Alkasurf O 75-9
CN Atlas G 2140
CN Atlas G 2141
CN Atlas G 2142
CN Atlas G 2143
CN Atlas G 2144
CN Atlas G 5507
CN Atlas G 5511
CN Blaunon O 600SA
CN Blaunon O 700SA
CN Cemulsol 1050
CN Cemulsol A
CN Cemulsol C 105
CN Cemulsol D 8
CN Chemax E 400MO
CN Chemester 3000C
CN Chimipon OCD
CN Cithrol 2MO
CN Cithrol PO
CN CRL 1337
CN Crodet O 100
CN Crodet O 40
CN Crodet O 6
CN Dyapol G
CN E2
CN Emalex 218
CN Emalex OE 1
CN Emalex OE 10
CN Emanon 4110
CN Emanon 4115
CN Emcol H 2A
CN Emcol H 31A
CN Emerest 2624
CN Emerest 2646
CN Emerest 2660
CN Empilan BP 100
CN Empilan BQ 100
CN Emulan A
CN Emulphor 24
CN Emulphor A
CN Emulphor VN 430
CN EN 1507
CN EN 1511
CN ES 120
CN *Monooleate ester of polyethylene glycol*
CN *Poly(ethylene glycol) oleic acid ester*
CN *Poly(oxyethylene) glycol monooleate*
CN *Polyethylene glycol monooleate*
CN *Polyethylene glycol oleate*
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 914926-86-6, 12772-84-8, 12789-13-8, 8013-78-3, 8051-25-0, 9007-68-5, 1341-62-4, 55126-82-4, 55945-62-5, 103939-39-5, 37223-98-6, 37223-99-7, 37330-99-7, 67775-15-9, 141927-22-2, 82905-19-9, 39316-40-0, 41139-27-9, 52504-20-8

MF (C2 H4 O)n C18 H34 O2
CI PMS, COM
PCT Polyether
LC STN Files: ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, IPA, MSDS-OHS, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1665 REFERENCES IN FILE CA (1907 TO DATE)
36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1668 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN *107-06-2* REGISTRY
ED Entered STN: 16 Nov 1984
CN Ethane, 1,2-dichloro- (CA INDEX NAME)
OTHER NAMES:
CN α,β-Dichloroethane
CN 1,2-Bichloroethane
CN 1,2-Dichlorethane
CN 1,2-Dichloroethane
CN 1,2-Ethylene dichloride
CN Brocide
CN DCE
CN Dichlor-Mulsion
CN Dutch liquid
CN EDC
CN EDC (halocarbon)
CN Ethylene chloride
CN Ethylene dichloride
CN *Glycol dichloride*
CN HCC 150
CN sym-Dichloroethane
DR 52399-93-6
MF C2 H4 Cl2
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15878 REFERENCES IN FILE CA (1907 TO DATE)
141 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
15913 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 57-55-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1,2-Propanediol (CA INDEX NAME)
OTHER NAMES:
CN (±)-1,2-Propanediol
CN (±)-Propylene glycol
CN (RS)-1,2-Propanediol
CN α-Propylene glycol
CN 1,2-(RS)-Propanediol
CN 1,2-Dihydroxypropane
CN 1,2-Propylene glycol
CN 1000PG
CN 2,3-Propanediol
CN 2-Hydroxypropanol
CN Adeka PG
CN Adeka Propylene Glycol PG-P
CN DC 403
CN DL-1,2-Propanediol
CN dl-Propylene glycol
CN Dowfrost
CN Isopropylene glycol
CN Methylethyl glycol
CN Methylethylene glycol
CN Monopropylene glycol
CN NSC 69860
CN Nybrine NFP
CN PG 12
CN PG-T
CN PG-T (glycol)
CN ProGlyc 55
CN Propylene glycol
CN Safewing MP-I 1938
CN Safewing MP-IV 2001
CN Sirlene
CN Solar Winter Ban
CN Solargard P
CN Ucar 35
DR 63625-56-9, 4254-16-4, 190913-75-8
MF C3 H8 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PATDPASPC, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

32647 REFERENCES IN FILE CA (1907 TO DATE)
3717 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
32747 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s l7 and ?coxib/cns
           31 ?COXIB/CNS
L9         10 L7 AND ?COXIB/CNS

=> d l9 1-10

L9   ANSWER 1 OF 10  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   639010-42-7  REGISTRY
ED   Entered STN:  19 Jan 2004
CN   Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
     yl]-, sodium salt, hydrate (1:1:?)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
     yl]-, monosodium salt, hydrate (9CI)
OTHER NAMES:
CN   Celecoxib sodium hydrate
MF   C17 H14 F3 N3 O2 S . x H2 O . Na
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
CRN  (169590-42-5)
```



● x H2O

● Na

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN 639010-36-9 REGISTRY
ED Entered STN: 19 Jan 2004
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, calcium salt (2:1) (CA INDEX NAME)
OTHER NAMES:
CN Celecoxib calcium
MF C17 H14 F3 N3 O2 S . 1/2 Ca
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (169590-42-5)



●1/2 Ca

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN 639010-35-8 REGISTRY
ED Entered STN: 19 Jan 2004
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, potassium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monopotassium salt (9CI)
OTHER NAMES:
CN Celecoxib potassium
MF C17 H14 F3 N3 O2 S . K
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (169590-42-5)



● K

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN 639010-34-7 REGISTRY
ED Entered STN: 19 Jan 2004
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, lithium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monolithium salt (9CI)
OTHER NAMES:
CN *Celecoxib lithium*
MF C17 H14 F3 N3 O2 S . Li
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (169590-42-5)



● Li

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN *639010-33-6* REGISTRY
ED Entered STN: 19 Jan 2004
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monosodium salt (9CI)
OTHER NAMES:
CN *Celecoxib sodium*
MF C17 H14 F3 N3 O2 S . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (169590-42-5)



● Na

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN *202409-33-4* REGISTRY
ED Entered STN: 11 Mar 1998
CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)
OTHER NAMES:
CN 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
CN Arcoxia
CN *Etoricoxib*
CN Kingcox
CN MK 0663
CN MK 663
CN Torcoxia
MF C18 H15 Cl N2 O2 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,

CASREACT, CHEMCATS, CSCHEM, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

603 REFERENCES IN FILE CA (1907 TO DATE)
28 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
609 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN *181695-72-7* REGISTRY
ED Entered STN: 10 Oct 1996
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)
OTHER NAMES:
CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CN Bextra
CN SC 65872
CN *Valdecoxib*
CN *Valecoxib*
CN Valus
CN Valz
MF C16 H14 N2 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

885 REFERENCES IN FILE CA (1907 TO DATE)
34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
889 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN *169590-42-5* REGISTRY
ED Entered STN: 02 Nov 1995
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)
OTHER NAMES:
CN 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
CN Celebra
CN Celebrex
CN Celecox
CN *Celecoxib*
CN *Celocoxib*
CN SC 58635
CN YM 177
DR 184007-95-2, 194044-54-7
MF C17 H14 F3 N3 O2 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3237 REFERENCES IN FILE CA (1907 TO DATE)
77 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3256 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN *169590-41-4* REGISTRY
ED Entered STN: 02 Nov 1995
CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)
OTHER NAMES:
CN 4-[5-(3-Fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
CN *Deracoxib*
CN Deram
CN Deramaxx
CN SC 046
CN SC 46
CN SC 59046
MF C17 H14 F3 N3 O3 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN, EMBASE, MEDLINE, MRCK*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

208 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
208 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2008 ACS on STN
RN *162011-90-7* REGISTRY
ED Entered STN: 07 Apr 1995
CN 2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl- (CA INDEX NAME)
OTHER NAMES:
CN 3-(4-Methanesulfonylphenyl)-2-phenyl-2-buten-4-olide
CN 3-Phenyl-4-[4-(Methylsulfonyl)phenyl]-2(5H)-furanone
CN 4-(4-(Methanesulfonyl)phenyl)-3-phenyl-5H-furan-2-one
CN 4-[(4-Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
CN MK 0966
CN MK 966
CN Rhuma-cure
CN *Rofecoxib*
CN Vioxx
DR 186912-82-3
MF C17 H14 O4 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2087 REFERENCES IN FILE CA (1907 TO DATE)
54 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2095 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.60	92.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:23:39 ON 24 DEC 2008